Given the finding that NF-κB signaling is highly activated in T/E fusion expressing cells, we sought to test the hypothesis that targeting NF-κB signaling may be a viable therapeutic approach for T/E fusion expressing PCa. This evidence concerns the gene NFKB1 and posterior cortical atrophy.